We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CASBF market cap is 447.63M. The company's latest EPS is CNY -11.1760 and P/E is -0.30.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 0 | 18.54M | 4.3B | 1.03B | 345.18M |
| Operating Income | -204.21M | -440.32M | 1.8B | -1.45B | -2.04B |
| Net Income | -156.77M | -396.64M | 1.91B | -909.43M | -1.48B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 1.78B | 6.75B | 11.87B | 11.47B | 9.32B |
| Total Liabilities | 313.98M | 677.22M | 3.33B | 4.22B | 4.03B |
| Total Equity | 1.47B | 6.07B | 8.55B | 7.25B | 5.29B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -170.19M | -469.39M | 2.01B | -1.89B | -916.25M |
| Investing | -797.77M | -182.71M | -2.53B | -1.19B | -441.62M |
| Financing | 1.09B | 4.92B | 1.56B | 854.6M | -7.58M |
| Market Cap | 447.63M |
| Price to Earnings Ratio | -0.30 |
| Price to Sales Ratio | 1.3 |
| Price to Cash Ratio | 0.22 |
| Price to Book Ratio | 0.08 |
| Dividend Yield | - |
| Shares Outstanding | 132.67M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 47.02% |
| 52 Week High | 4.35 |
| 52 Week Low | 1.86 |
| Spread (Intraday) | 0.47 (9.92%) |
| Company Name | Cansino Biologics Inc (PK) |
| Address |
401-420, 4th floor tianjin |
| Website | https://www.cansinotech.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
